Oruka Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Oruka Therapeutics, Inc. (ORKA) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value of $7.80 per share as of 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2024-11-13
- 2024-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $7.80.
- 2023-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $2.21.
- 2023-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $2.21.
- 2023-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $2.21.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value as first filed |
|---|---|---|
| 2024-09-30 | $7.80 10-Q · filed 2024-11-13 | |
| 2023-09-30 | $2.21 10-Q · filed 2023-10-18 | |
| 2023-06-30 | $2.21 10-Q · filed 2023-07-21 | |
| 2023-03-31 | $2.21 10-Q · filed 2023-04-24 | |
| 2022-12-31 | $2.21 10-K · filed 2024-02-01 | |
| 2018-09-30 | $5.23 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $5.23 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $4.75 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $142.92 10-K · filed 2020-02-18 | $7.94 10-K · filed 2018-03-22 |
| 2017-09-30 | $7.90 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $7.90 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $6.69 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $7.91 10-K · filed 2019-02-27 | |
| 2016-09-30 | $8.02 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $8.53 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $7.88 10-Q · filed 2016-05-11 | |
| 2015-12-31 | $8.36 10-K · filed 2018-03-22 | |
| 2015-09-30 | $8.79 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $1.28 10-Q · filed 2015-08-11 | |
| 2015-03-31 | $1.29 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $11.33 10-K · filed 2017-03-21 | $1.62 10-K · filed 2015-03-19 |
| 2014-09-30 | $1.61 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $1.57 10-Q · filed 2014-08-13 | |
| 2014-03-31 | $1.57 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $9.75 10-K · filed 2016-03-17 | $1.39 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |